Skip to main content

Why Big Pharma's main argument about drug prices doesn't hold up, according to Rep. Katie Porter

By Yahoo! Finance  
   April 27, 2022

Porter noted that between 2013 to 2018, just $2.45 billion was spent on R&D while $4.71 billion was spent on marketing and $334 million on executive compensation. Additionally, the company spent $50 billion on stock buybacks, the congresswoman said.

Full story


Get the latest on healthcare leadership in your inbox.